{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:18:28Z","timestamp":1791299908995,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells\n                    <jats:italic>via<\/jats:italic>\n                    major histocompatibility complex class II (MHC-II) and to CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells\n                    <jats:italic>via<\/jats:italic>\n                    major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1255799","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:21:09Z","timestamp":1693891269000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Hong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peigen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000134734","article-title":"Genomic cloning and localization of ctag, a gene encoding an autoimmunogenic cancer-testis antigen ny-eso-1, to human chromosome xq28","volume":"79","author":"Chen","year":"1997","journal-title":"Cytogenet Cell Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"Ny-eso-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00947","article-title":"Ny-eso-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.133","article-title":"The cancer-testis antigen ny-eso-1 is highly expressed in myxoid and round cell subset of liposarcomas","volume":"26","author":"Hemminger","year":"2013","journal-title":"Mod Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27446","article-title":"Ny-eso-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid\/round cell liposarcoma","volume":"118","author":"Pollack","year":"2012","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen ny-eso-1 but not mage-A1 or ct7","volume":"94","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"B7","article-title":"Ny-eso-1 and lage-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res"},{"key":"B8","article-title":"Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of ny-eso-1 tumor antigen","volume":"63","author":"Rodolfo","year":"2003","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-023-01807-w","article-title":"The use of rna-based treatments in the field of cancer immunotherapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e49020","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"Elife"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1590\/s1517-83822014000400001","article-title":"Live bacterial vaccine vectors: an overview","volume":"45","author":"da Silva","year":"2014","journal-title":"Braz J Microbiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28045","article-title":"In vivo antigen delivery by a salmonella typhimurium type iii secretion system for therapeutic cancer vaccines","volume":"116","author":"Nishikawa","year":"2006","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113761","article-title":"Induction of regulatory T cell-resistant helper cd4+ T cells by bacterial vector","volume":"111","author":"Nishikawa","year":"2008","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/s1357-4310(99)01633-0","article-title":"Recent advances with recombinant bacterial vaccine vectors","volume":"6","author":"Shata","year":"2000","journal-title":"Mol Med Today"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm1039","article-title":"Dendritic cell immunotherapy: mapping the way","volume":"10","author":"Figdor","year":"2004","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","article-title":"Dendritic-cell-based therapeutic cancer vaccines","volume":"39","author":"Palucka","year":"2013","journal-title":"Immunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1019197","article-title":"Intranodal vaccination with mrna-optimized dendritic cells in metastatic melanoma patients","volume":"4","author":"Bol","year":"2015","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31205","article-title":"Dc-based cancer vaccines","volume":"117","author":"Gilboa","year":"2007","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00139.x","article-title":"Cancer immunotherapy with mrna-transfected dendritic cells","volume":"199","author":"Gilboa","year":"2004","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0952-7915(03)00015-3","article-title":"The use of dendritic cells in cancer immunotherapy","volume":"15","author":"Schuler","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.v98.1.49","article-title":"Highly efficient gene delivery by mrna electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mrna and to electroporation of plasmid cdna for tumor antigen loading of dendritic cells","volume":"98","author":"Van Tendeloo","year":"2001","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e006930","DOI":"10.1136\/jitc-2023-006930","article-title":"Immunotherapy resistance driven by loss of ny-eso-1 expression in response to transgenic adoptive cellular therapy with pd-1 blockade","volume":"11","author":"Frankiw","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03452","article-title":"Phase ii randomized study of cmb305 and atezolizumab compared with atezolizumab alone in soft-tissue sarcomas expressing ny-eso-1","volume":"40","author":"Chawla","year":"2022","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000183","article-title":"First-in-human treatment with a dendritic cell-targeting lentiviral vector-expressing ny-eso-1, lv305, induces deep, durable response in refractory metastatic synovial sarcoma patient","volume":"40","author":"Pollack","year":"2017","journal-title":"J Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2632","article-title":"Ny-eso-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells","volume":"15","author":"Gnjatic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1169353","DOI":"10.1080\/2162402X.2016.1169353","article-title":"Scib2, an antibody DNA vaccine encoding ny-eso-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade","volume":"5","author":"Xue","year":"2016","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102405","article-title":"The paradigm shift in treatment from covid-19 to oncology with mrna vaccines","volume":"107","author":"Wei","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mrna vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.132","article-title":"An rna toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/BF01519900","article-title":"Characterization of a messenger rna polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9","article-title":"An rna vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/iia study of the mrna-based cancer immunotherapy cv9201 in patients with stage iiib\/iv non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase ib evaluation of a self-adjuvanted protamine formulated mrna-based active cancer immunotherapy, bi1361849 (Cv9202), combined with local radiation treatment in patients with stage iv non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase ib study evaluating a self-adjuvanted mrna cancer vaccine (Rnactive(R)) combined with local radiation as consolidation and maintenance treatment for patients with stage iv non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1511506","article-title":"Trial watch: peptide-based vaccines in anticancer therapy","volume":"7","author":"Bezu","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2062982","article-title":"The progress of peptide vaccine clinical trials in gynecologic oncology","volume":"18","author":"Tang","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2010.02.006","article-title":"Dc-Expressed Mhc Class I Single-Chain Trimer-Based Vaccines Prime Cytotoxic T Lymphocytes against Exogenous but Not Endogenous Antigens","volume":"262","author":"Ordaz","year":"2010","journal-title":"Cell Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048424","article-title":"A cancer vaccine induces expansion of ny-eso-1-specific regulatory T cells in patients with advanced melanoma","volume":"7","author":"Ebert","year":"2012","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2484","article-title":"Regulatory T-cell-mediated attenuation of T-cell responses to the ny-eso-1 iscomatrix vaccine in patients with advanced Malignant melanoma","volume":"15","author":"Nicholaou","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403572101","article-title":"Recombinant ny-eso-1 protein with iscomatrix adjuvant induces broad integrated antibody and cd4(+) and cd8(+) T cell responses in humans","volume":"101","author":"Davis","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acsabm.0c00259","article-title":"Cowpea mosaic virus (Cpmv)-based cancer testis antigen ny-eso-1 vaccine elicits an antigen-specific cytotoxic T cell response","volume":"3","author":"Patel","year":"2020","journal-title":"ACS Appl Bio Mater"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1459394","article-title":"Adjuvants: classification, modus operandi, and licensing","volume":"2016","author":"Apostolico Jde","year":"2016","journal-title":"J Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02892-w","article-title":"Safety and antibody immune response of chp-ny-eso-1 vaccine combined with poly-iclc in advanced or recurrent esophageal cancer patients","volume":"70","author":"Ishikawa","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2326-6066.CIR-19-0545","article-title":"Combined vaccination with ny-eso-1 protein, poly-iclc, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma","volume":"8","author":"Pavlick","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000162","article-title":"Ny-eso-1 protein cancer vaccine with poly-iclc and ok-432: rapid and strong induction of ny-eso-1-specific immune responses by poly-iclc","volume":"40","author":"Takeoka","year":"2017","journal-title":"J Immunother"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0089","article-title":"Effect of montanide and poly-iclc adjuvant on human self\/tumor antigen-specific cd4+ T cells in phase I overlapping long peptide vaccine trial","volume":"1","author":"Tsuji","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of Malignant melanoma patients with full-length ny-eso-1 protein using tlr7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"Adams","year":"2008","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02483-1","article-title":"First-in-human phase I clinical trial of the ny-eso-1 protein cancer vaccine with nod2 and tlr9 stimulants in patients with ny-eso-1-expressing refractory solid tumors","volume":"69","author":"Ishihara","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25955","article-title":"A phase I study of vaccination with ny-eso-1f peptide mixed with picibanil ok-432 and montanide isa-51 in patients with cancers expressing the ny-eso-1 antigen","volume":"129","author":"Kakimi","year":"2011","journal-title":"Int J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0703395104","article-title":"Vaccination with ny-eso-1 protein and cpg in montanide induces integrated antibody\/th1 responses and cd8 T cells through cross-priming","volume":"104","author":"Valmori","year":"2007","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24850","article-title":"Tumor-reactive cd8+ T-cell responses after vaccination with ny-eso-1 peptide, cpg 7909 and montanide isa-51: association with survival","volume":"126","author":"Karbach","year":"2010","journal-title":"Int J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and immunogenicity study of ny-eso-1b peptide and montanide isa-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1811","article-title":"Efficient in vivo priming by vaccination with recombinant ny-eso-1 protein and cpg in antigen naive prostate cancer patients","volume":"17","author":"Karbach","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e003220","DOI":"10.1136\/jitc-2021-003220","article-title":"Phase I\/ii trial of a long peptide vaccine (Lpv7) plus toll-like receptor (Tlr) agonists with or without incomplete freund\u2019s adjuvant (Ifa) for resected high-risk melanoma","volume":"9","author":"Patel","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with lag-3ig (Imp321) and peptides induces specific cd4 and cd8 T-cell responses in metastatic melanoma patients\u2013report of a phase I\/iia clinical trial","volume":"22","author":"Legat","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1216290","article-title":"Vaccination of stage iii\/iv melanoma patients with long ny-eso-1 peptide and cpg-B elicits robust cd8(+) and cd4(+) T-cell responses with multiple specificities including a novel dr7-restricted epitope","volume":"5","author":"Baumgaertner","year":"2016","journal-title":"Oncoimmunology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-246","article-title":"Dose-dependent effects of ny-eso-1 protein vaccine complexed with cholesteryl pullulan (Chp-ny-eso-1) on immune responses and survival benefits of esophageal cancer patients","volume":"11","author":"Kageyama","year":"2013","journal-title":"J Transl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-iclc shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1656-x","article-title":"Low-dose cyclophosphamide enhances antigen-specific cd4(+) T cell responses to ny-eso-1\/iscomatrix vaccine in patients with advanced melanoma","volume":"64","author":"Klein","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000161398.34701.26","article-title":"Distinct structural tcr repertoires in naturally occurring versus vaccine-induced cd8+ T-cell responses to the tumor-specific antigen ny-eso-1","volume":"28","author":"Le Gal","year":"2005","journal-title":"J Immunother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182a80263","article-title":"Enhancing whole-tumor cell vaccination by engaging innate immune system through ny-eso-1\/dendritic cell interactions","volume":"36","author":"Xu","year":"2013","journal-title":"J Immunother"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox ny-eso-1 vaccines induce both humoral and cellular ny-eso-1-specific immune responses in cancer patients","volume":"103","author":"Jager","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing ny-eso-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eccc87","article-title":"Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma","volume":"33","author":"Vogel","year":"2010","journal-title":"J Immunother"},{"key":"B75","first-page":"12","article-title":"Ny-eso-1-specific immunological pressure and escape in a patient with metastatic melanoma","volume":"13","author":"von Boehmer","year":"2013","journal-title":"Cancer Immun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav8692","article-title":"Enhanced Car-T Cell Activity against Solid Tumors by Vaccine Boosting through the Chimeric Receptor","volume":"365","author":"Ma","year":"2019","journal-title":"Science"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted car T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.05.490779","article-title":"Lymph node-targeted vaccine boosting of tcr-T cell therapy enhances anti-tumor function and eradicates solid tumors","author":"Drakes","year":"2022","journal-title":"bioRxiv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1255799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:21:13Z","timestamp":1693891273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1255799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2023.1255799"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1255799","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"article-number":"1255799"}}